Thursday, November 12, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 16, 2025

XRP Lost Over 45% Since July Peak: Can $1B ETF Momentum Reverse the Slide?

View original at finance.yahoo.com
XRP Lost Over 45% Since July Peak: Can $1B ETF Momentum Reverse the Slide? Tamisclao / Shutterstock.com Quick Read XRP dropped from $3.66 in July 2025 to around $2.00 by December 2025, losing over 45% as 37% of holders sit on unrealized losses U.S…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Technical forecasts suggest a break under $2.00 may target $1.90-1.95 initially, with deeper slides to $1.50 possible if the downtrend intensifies

    80% confidence

  • If XRP ETF inflows continue at current trends, the float may shrink by another 2-3% by Q1 2026

    80% confidence

  • The SEC's approval regime and court rulings characterizing XRP as a commodity made it a compliance-friendly token for advisors

    80% confidence

  • XRP could approach its old $3.66 high by late 2026, driven by shrinking exchange float and steady institutional accumulation

    80% confidence

  • Analysts argue these institutional XRP ETF inflows create a structural bid under XRP

    80% confidence

  • Approximately 37% of XRP's circulating supply sits in unrealized loss

    80% confidence

  • Since mid-November, U.S. XRP ETF inflows amassed over $1 billion and absorbed nearly 1% of XRP's circulating supply

    80% confidence

  • This supply squeeze mirrors what happened to Bitcoin after ETF approval—shrinking float, then rallies

    80% confidence

Data points we hold from this source

XRP · unrealized loss percentage37 percent
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com
XRP Lost Over 45% Since July Peak: Can $1B ETF Momentum Reverse the Slide? — Source | Via News | Via News